Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life

Julia Boyle, Malin E V Eriksson, Laura Gribble, Ravi Gouni, Sigurd Johnsen, David V Coppini, David Kerr, Julia Boyle, Malin E V Eriksson, Laura Gribble, Ravi Gouni, Sigurd Johnsen, David V Coppini, David Kerr

Abstract

Objective: Chronic diabetic peripheral neuropathic pain (DPNP) is difficult to treat, with treatment regimens often inadequate at controlling pain and limited by side effects and drug tolerance. Secondary parameters, such as quality of sleep and mood, may also be important for successful DPNP management. The objectives of this study were to compare the analgesic efficacy of pregabalin, amitriptyline, and duloxetine, and their effect on polysomnographic sleep, daytime functioning, and quality of life in patients with DPNP.

Research design and methods: This was a double-blind, randomized, parallel group investigation of type 1 and 2 diabetic subjects with DPNP. Each treatment group had a single-blind, 8-day, placebo run-in followed by 14 days of lower-dose and 14 days of higher-dose medication. At the end of each dose titration period, subjective pain, sleep, and daytime functioning were assessed during a 2-day residential period.

Results: All medications reduced pain when compared with placebo, but no one treatment was superior to any other. For sleep, pregabalin improved sleep continuity (P < 0.001), whereas duloxetine increased wake and reduced total sleep time (P < 0.01 and P < 0.001). Despite negative effects on sleep, duloxetine enhanced central nervous system arousal and performance on sensory motor tasks. There were no significant safety findings; however, there was a significantly higher number of adverse events in the pregabalin treatment group.

Conclusions: There was no significant difference in analgesic efficacy between amitriptyline, duloxetine, and pregabalin. However, there were significant differences in the secondary parameters, which may be of relevance when deciding the optimal treatment for DPNP.

Trial registration: ClinicalTrials.gov NCT00370656.

Figures

Figure 1
Figure 1
A schematic illustrating the timing of the main study procedures. CGMS, continuous glucose monitoring system; GTB, Guildford test battery (CFF, CRT, CTT, Stroop test, Sternberg short-term memory scanning task, DSST, word recall, Leeds Sleep Evaluation Questionnaire, and linear analog scales). GTB training was at 10:00, 13:00, and 16:00 on day 7, 21, and 35. GTB testing was at 08:00, 10:00, 13:00, and 16:00 on day 8, 22, and 36.

References

    1. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004;61:160–173; quiz 175–176
    1. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM 1998;91:733–737
    1. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123–128
    1. O’Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27:95–112
    1. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004;88:947–999, xi
    1. Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237–251
    1. Moulin DE, Clark AJ, Gilron I, et al. Canadian Pain Society Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13–21
    1. Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med 2007;24:377–383
    1. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000;20:280–285
    1. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109–118
    1. Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag 2007;3:833–844
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149:360–364
    1. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254–263
    1. Asplund R. Nocturia, nocturnal polyuria, and sleep quality in the elderly. J Psychosom Res 2004;56:517–525
    1. Resnick HE, Redline S, Shahar E, et al. Sleep Heart Health Study Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care 2003;26:702–709
    1. Lopes LA, Lins CdeM, Adeodato VG, et al. Restless legs syndrome and quality of sleep in type 2 diabetes. Diabetes Care 2005;28:2633–2636
    1. Bendtson I, Gade J, Theilgaard A, Binder C. Cognitive function in type 1 (insulin-dependent) diabetic patients after nocturnal hypoglycaemia. Diabetologia 1992;35:898–903
    1. Pallayova M, Donicova V, Donic V. Association between nocturnal hyperglycaemia and severe sleep-disordered breathing in type 2 diabetic patients: a study based on continuous glucose monitoring. Diabetologia 2006;49(Suppl. 1):152
    1. Moldofsky H. Sleep and pain. Sleep Med Rev 2001;5:385–396
    1. Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP., Jr Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008;12:203–213
    1. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005;28:187–193
    1. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001;92:147–157
    1. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health 1999;53:46–50
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129–138
    1. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191–197
    1. Zisapel N, Laudon M. Subjective assessment of the effects of CNS-active drugs on sleep by the Leeds sleep evaluation questionnaire: a review. Hum Psychopharmacol 2003;18:1–20
    1. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980;10:189–209
    1. Gillberg M, Kecklund G, Akerstedt T. Relations between performance and subjective ratings of sleepiness during a night awake. Sleep 1994;17:236–241
    1. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System of Sleep Stages in Human Subjects. Washington, DC, U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, 1968
    1. Wechsler D. Wechsler Adult Intelligence Scale - Revised. New York, The Psychological Corporation, 1981
    1. Baddeley AWM. A Working Memory. OUP, Oxford. Oxford, OUP, 1986
    1. Sternberg S. High-speed scanning in human memory. Science 1966;153:652–654
    1. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250–1256
    1. Fairweather DB, Kerr JS, Hilton S, Hindmarch I. A placebo controlled double-blind evaluation of the pharmacodynamics of fengabine vs. amitriptyline following single and multiple doses in elderly volunteers. Br J Clin Pharmacol 1993;35:278–283
    1. Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl) 2005;183:133–143
    1. Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Guzmán D, Guàrdia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res 2009;43:855–863
    1. Chalon S, Pereira A, Lainey E, et al. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl) 2005;177:357–365
    1. Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. Harv Rev Psychiatry 2000;8:298–306
    1. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008;43:70–75
    1. Saletu-Zyhlarz GM, Mandl M, Gruber G, Divos H, Jenull B, Saletu B. Placebo-controlled polysomnographic and psychometric studies on the acute effects of pregabalin in insomnia related to neurotic and stress-related disorders and sleep-related movement disorders. J Sleep Res 2006;15(Suppl. 1):40

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner